Literature DB >> 30199854

Early Achievement of Blood Pressure Lowering and Hematoma Growth in Acute Intracerebral Hemorrhage: Stroke Acute Management with Urgent Risk-Factor Assessment and Improvement-Intracerebral Hemorrhage Study.

Yoshitaka Yamaguchi1, Masatoshi Koga2, Shoichiro Sato3, Hiroshi Yamagami3,2, Kenichi Todo4, Satoshi Okuda5, Yasushi Okada6, Kazumi Kimura7, Yoshiaki Shiokawa8, Kenji Kamiyama9, Ryo Itabashi10, Yasuhiro Hasegawa11, Kazuomi Kario12, Kyohei Fujita3, Masaya Kumamoto3, Teppei Kamimura13, Daisuke Ando3, Toshihiro Ide3, Takeshi Yoshimoto13, Masayuki Shiozawa3, Soichiro Matsubara3, Sohei Yoshimura3, Kazuyuki Nagatsuka13, Kazunori Toyoda3.   

Abstract

BACKGROUND: Previous studies have revealed that hematoma growth mainly occurs during the first 6 h after the onset of spontaneous intracerebral hemorrhage (ICH). Early lowering of blood pressure (BP) may be beneficial for preventing hematoma growth. However, relationships between timing of BP lowering and hematoma growth in ICH remain unclear. We investigated associations between timing of BP lowering and hematoma growth for ICH.
METHODS: The Stroke Acute Management with Urgent Risk-factor Assessment and Improvement (SAMURAI)-ICH Study was a multicenter, prospective, observational study investigating the safety and feasibility of early (within 3 h from onset) reduction of systolic BP (SBP) to < 160 mm Hg with intravenous nicardipine for acute hypertension in cases of spontaneous ICH. The present study was a post hoc analysis of the SAMURAI-ICH study. We examined relationships between time from onset, imaging, and initiation of treatment to target SBP achievement and hematoma growth (absolute growth ≥6 mL) in ICH patients. Target SBP achievement was defined as the time at which SBP first became < 160 mm Hg.
RESULTS: Among 211 patients, hematoma growth was seen in 31 patients (14.7%). The time from imaging to target SBP and time from treatment to target SBP were significantly shorter in patients without hematoma growth than in those with (p = 0.043 and p = 0.032 respectively), whereas no significant difference was seen in time from onset to SBP < 160 mm Hg between groups (p = 0.177). Patients in the lower quartiles of time from imaging to target SBP and time from treatment to target SBP showed lower incidences of hematoma growth (p trend = 0.023 and 0.037 respectively). The lowest quartile of time from imaging to target SBP (< 38 min) was negatively associated with hematoma growth on multivariable logistic regression (OR 0.182; 95% CI 0.038-0.867; p = 0.032).
CONCLUSIONS: Early achievement of target SBP < 160 mm Hg is associated with a lower risk of hematoma growth in ICH.
© 2018 S. Karger AG, Basel.

Entities:  

Keywords:  Antihypertensive treatment; Hypertension; Intracerebral hemorrhage; Nicardipine; Stroke; Systolic blood pressure

Mesh:

Substances:

Year:  2018        PMID: 30199854     DOI: 10.1159/000492728

Source DB:  PubMed          Journal:  Cerebrovasc Dis        ISSN: 1015-9770            Impact factor:   2.762


  3 in total

1.  2022 Guidelines of the Taiwan Society of Cardiology and the Taiwan Hypertension Society for the Management of Hypertension.

Authors:  Tzung-Dau Wang; Chern-En Chiang; Ting-Hsing Chao; Hao-Min Cheng; Yen-Wen Wu; Yih-Jer Wu; Yen-Hung Lin; Michael Yu-Chih Chen; Kwo-Chang Ueng; Wei-Ting Chang; Ying-Hsiang Lee; Yu-Chen Wang; Pao-Hsien Chu; Tzu-Fan Chao; Hsien-Li Kao; Charles Jia-Yin Hou; Tsung-Hsien Lin
Journal:  Acta Cardiol Sin       Date:  2022-05       Impact factor: 1.800

2.  Probability assessment of intracerebral hemorrhage in prehospital emergency patients.

Authors:  Frederik Geisler; Medschid Wesirow; Martin Ebinger; Alexander Kunz; Michal Rozanski; Carolin Waldschmidt; Joachim E Weber; Matthias Wendt; Benjamin Winter; Heinrich J Audebert
Journal:  Neurol Res Pract       Date:  2021-01-06

3.  Regional Differences in the Response to Acute Blood Pressure Lowering After Cerebral Hemorrhage.

Authors:  Kazunori Toyoda; Yuko Y Palesch; Masatoshi Koga; Lydia Foster; Haruko Yamamoto; Sohei Yoshimura; Masafumi Ihara; Mayumi Fukuda-Doi; Shuhei Okazaki; Kanta Tanaka; Kaori Miwa; Yasuhiro Hasegawa; Yoshiaki Shiokawa; Toru Iwama; Kenji Kamiyama; Haruhiko Hoshino; Thorsten Steiner; Byung-Woo Yoon; Yongjun Wang; Chung Y Hsu; Adnan I Qureshi
Journal:  Neurology       Date:  2020-11-20       Impact factor: 9.910

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.